Dr. Jarrard Responds to PSA Studies
Several media outlets have reported urologic oncologist David Jarrard M.D.’s response to two recently publicized studies (done elsewhere) that found similar mortality rates for patients who received the prostate-specific antigen (PSA) screening test for prostate cancer and those who did not, during a seven to nine year follow-up period.
“Screening is more likely to benefit younger individuals and those with over a 10 to 15 year expected lifespan,” says Jarrard. He points out that a more aggressive form of the disease kills about 30,000 American men each year, and screening needs to be individualized.
“This is a discussion that men need to have with their doctors," he says. The full press release can be found on the UW Health website